Professor O'Brien (UCL and The Royal Free) used to run a laboratory group but was lucky enough to progress an idea from bench to trial and, even though it did not work, found he much preferred doing clinical trials in cirrhosis. He has been very fortunate to deliver the ATTIRE & ASEPTIC UK clinical trials and will shortly begin another, even larger trial, APEACH (The Apixaban to Prevent dEcompensation of eArly liver CirrHosis trial). Hopefully he will be able to do at least one or two more following this daunting task.

Dr. Do is a board-certified hepatologist and Clinical Associate Professor of Medicine at UC Davis Health, where he specializes in general and transplant hepatology, seeing all types of liver diseases and with a passion for steatotic liver disease (metabolic and alcohol-associated liver disease). He provides care to patients with a broad spectrum of general hepatology conditions and is also a member of the UC Davis Liver Transplant Center, offering expertise in pre- and post-transplant management. Dr.

Nadim Mahmud, MD MS MPH MSCE is an Assistant Professor of Medicine and Epidemiology at the Hospital of the University of Pennsylvania

Dr. Fontana is a Professor of Medicine in the Division of Gastroenterology & Hepatology at the University of Michigan. Over the past 2 decades, Dr Fontana has been involved in prospective registry studies regarding the etiologies and outcomes of acute liver failure and idiosyncratic DILI and clinical trials in viral hepatitis. Dr. Fontana is the Co-PI of the Drug Induced Liver Injury Network Steering Committee and is conducting studies on genetic susceptibility factors and outcomes of DILI.

Tamir Diamond MD MSTR is a transplant hepatologist at Children's Hospital of Philadelphia and an assistant professor of pediatrics at Perelman School of Medicine, University of Pennsylvania. His research interest focuses on immune mechanisms of Pediatric and Neonatal Acute Liver Failure. He is a member of the inaugural Clinical In Vivo Gene Therapy team at Children's Hospital of Philadelphia, the first interdisciplinary team in the US focusing on treating complications arising for children receiving novel Gene therapies.

Dr. Elizabeth Phillips is a physician scientist clinically trained in Infectious diseases, immunology and clinical pharmacology who has established new clinical and research programs in drug hypersensitivity, pharmacogenomics and personalized immunology across different healthcare systems. She has published over 450 peer reviewed articles and book chapters related to hypersensitivity reactions to drugs and vaccines.

Dr. Jonathan Sexton is faculty in the Department of Internal Medicine in the Division of Gastroenterology and Hepatology, and the College of Pharmacy, Medicinal Chemistry at the University of Michigan. Dr. Sexton is a translational scientist with expertise in artificial intelligence-enhanced drug discovery and development. His research focuses on advancing lead compounds toward clinical applications in various therapeutic areas, particularly in liver and gastrointestinal diseases.

.

I am a transplant hepatologist with a research focus at the intersection of nephrology and hepatology.

Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta. <br><br>He did his MD at the University of Santiago de Compostela, Spain, and got his GI and hepatology training in Barcelona. He did a postdoctoral training at Yale University (2003–2004). <br><br>His main interest is the diagnosis, risk prediction and management of chronic liver disease. He has co-chaired the AASLD guidelines for TIPS and RT0 (2024), and co-authored the AASLD portal hypertension guidelines (2016).